114 related articles for article (PubMed ID: 34111705)
1. Clinical utility of the imunohistochemical co-expression of p53 and MDM2 in thyroid follicular lesions.
Martins MB; de Assis Batista F; Marcello MA; Bufalo NE; Peres KC; Morari EC; Soares FA; Vassallo J; Ward LS
Ann Diagn Pathol; 2021 Aug; 53():151766. PubMed ID: 34111705
[TBL] [Abstract][Full Text] [Related]
2. APLP2, RRM2, and PRC1: New Putative Markers for the Differential Diagnosis of Thyroid Follicular Lesions.
Castelblanco E; Zafon C; Maravall J; Gallel P; Martinez M; Capel I; Bella MR; Halperin I; Temprana J; Iglesias C; Puig-Domingo M; Robledo M; Matias-Guiu X; Mauricio D
Thyroid; 2017 Jan; 27(1):59-66. PubMed ID: 27796194
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of p53 protein and MDM2 in papillary carcinomas of the thyroid: Correlations with clinicopathologic features.
Horie S; Maeta H; Endo K; Ueta T; Takashima K; Terada T
Pathol Int; 2001 Jan; 51(1):11-5. PubMed ID: 11148457
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical expression of HBME-1 and galectin-3 in the differential diagnosis of follicular-derived thyroid nodules.
Abd-El Raouf SM; Ibrahim TR
Pathol Res Pract; 2014 Dec; 210(12):971-8. PubMed ID: 25041837
[TBL] [Abstract][Full Text] [Related]
5. Muc-1 expression may help characterize thyroid nodules but does not predict patients' outcome.
Morari EC; Silva JR; Guilhen AC; Cunha LL; Marcello MA; Soares FA; Vassallo J; Ward LS
Endocr Pathol; 2010 Dec; 21(4):242-9. PubMed ID: 21057891
[TBL] [Abstract][Full Text] [Related]
6. Clinical utility of KAP-1 expression in thyroid lesions.
Martins MB; Marcello MA; Morari EC; Cunha LL; Soares FA; Vassallo J; Ward LS
Endocr Pathol; 2013 Jun; 24(2):77-82. PubMed ID: 23645532
[TBL] [Abstract][Full Text] [Related]
7. Role of cd56 and e-cadherin expression in the differential diagnosis of papillary thyroid carcinoma and suspected follicular-patterned lesions of the thyroid: the prognostic importance of e-cadherin.
Ceyran AB; Şenol S; Şimşek BÇ; Sağıroğlu J; Aydın A
Int J Clin Exp Pathol; 2015; 8(4):3670-80. PubMed ID: 26097548
[TBL] [Abstract][Full Text] [Related]
8. Predictive value of cell cycle markers p53, MDM2, p21, and Ki-67 in superficial bladder tumor recurrence.
Pfister C; Moore L; Allard P; Larue H; Lacombe L; Têtu B; Meyer F; Fradet Y
Clin Cancer Res; 1999 Dec; 5(12):4079-84. PubMed ID: 10632343
[TBL] [Abstract][Full Text] [Related]
9. P53 and expression of immunological markers may identify early stage thyroid tumors.
Marcello MA; Morari EC; Cunha LL; De Nadai Silva AC; Carraro DM; Carvalho AL; Soares FA; Vassallo J; Ward LS
Clin Dev Immunol; 2013; 2013():846584. PubMed ID: 24171036
[TBL] [Abstract][Full Text] [Related]
10. Role of Ultrasound in Predicting Tumor Invasiveness in Follicular Variant of Papillary Thyroid Carcinoma.
Hahn SY; Shin JH; Oh YL; Kim TH; Lim Y; Choi JS
Thyroid; 2017 Sep; 27(9):1177-1184. PubMed ID: 28699414
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic utility of CK19 and CD56 in the differentiation of thyroid papillary carcinoma from its mimics.
Abouhashem NS; Talaat SM
Pathol Res Pract; 2017 May; 213(5):509-517. PubMed ID: 28214214
[TBL] [Abstract][Full Text] [Related]
12. An antibody-like peptide that recognizes malignancy among thyroid nodules.
Reis CF; Carneiro AP; Vieira CU; Fujimura PT; Morari EC; Silva SJ; Goulart LR; Ward LS
Cancer Lett; 2013 Jul; 335(2):306-13. PubMed ID: 23462224
[TBL] [Abstract][Full Text] [Related]
13. Ultrasound Risk Assessment Combined with Molecular Markers of Galectin-3, c-MET, HBME-1 and CK19 for Diagnosis of Malignant and Benign Thyroid Nodules.
Han RL; Wang J; Zhang FJ; Zhao N; Gao BL
Pathol Oncol Res; 2019 Jul; 25(3):1075-1081. PubMed ID: 30361909
[TBL] [Abstract][Full Text] [Related]
14. Restoration of p53 using the novel MDM2-p53 antagonist APG115 suppresses dedifferentiated papillary thyroid cancer cells.
Chen H; Luo D; Zhang L; Lin X; Luo Q; Yi H; Wang J; Yan X; Li B; Chen Y; Liu X; Zhang H; Liu S; Qiu M; Yang D; Jiang N
Oncotarget; 2017 Jun; 8(26):43008-43022. PubMed ID: 28498808
[TBL] [Abstract][Full Text] [Related]
15. Gene expression of thyroid-specific transcription factors may help diagnose thyroid lesions but are not determinants of tumor progression.
Batista FA; Ward LS; Marcello MA; Martins MB; Peres KC; Torricelli C; Bufalo NE; Soares FA; da Silva MJ; Assumpção LV
J Endocrinol Invest; 2016 Apr; 39(4):423-9. PubMed ID: 26370671
[TBL] [Abstract][Full Text] [Related]
16. Comparison of proliferating cell nuclear antigen, thyroid transcription factor-1, Ki-67, p63, p53 and high-molecular weight cytokeratin expressions in papillary thyroid carcinoma, follicular carcinoma, and follicular adenoma.
Tan A; Etit D; Bayol U; Altinel D; Tan S
Ann Diagn Pathol; 2011 Apr; 15(2):108-16. PubMed ID: 21315633
[TBL] [Abstract][Full Text] [Related]
17. Cell cycle regulators show diagnostic and prognostic utility for differentiated thyroid cancer.
Melck A; Masoudi H; Griffith OL; Rajput A; Wilkins G; Bugis S; Jones SJ; Wiseman SM
Ann Surg Oncol; 2007 Dec; 14(12):3403-11. PubMed ID: 17882495
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical Subcellular Localization of Protein Biomarkers Distinguishes Benign from Malignant Thyroid Nodules: Potential for Fine-Needle Aspiration Biopsy Clinical Application.
Ralhan R; Veyhl J; Chaker S; Assi J; Alyass A; Jeganathan A; Somasundaram RT; MacMillan C; Freeman J; Vescan AD; Witterick IJ; Walfish PG
Thyroid; 2015 Nov; 25(11):1224-34. PubMed ID: 26131603
[TBL] [Abstract][Full Text] [Related]
19. P53 and MDM2 Over-expression and Five-year Survival of Kidney Cancer Patients Undergoing Radical Nephrectomy--Iranian Experience.
Abolhasani M; Salarinejad S; Asgari M
Asian Pac J Cancer Prev; 2015; 16(12):5043-7. PubMed ID: 26163638
[TBL] [Abstract][Full Text] [Related]
20. Prevalences of Gs alpha, ras, p53 mutations and ret/PTC rearrangement in differentiated thyroid tumours in a Korean population.
Park KY; Koh JM; Kim YI; Park HJ; Gong G; Hong SJ; Ahn IM
Clin Endocrinol (Oxf); 1998 Sep; 49(3):317-23. PubMed ID: 9861322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
